Current News Today

- Advertisement -

- Advertisement -

Big Chile study finds Chinese vaccine slashes COVID deaths


A study of millions of Chileans who have received the Chinese-developed CoronaVac vaccine has found it 67% effective against symptoms and 80% against death from COVID-19

SANTIAGO, Chile — A real-world study of millions of Chileans who had received the Chinese-developed CoronaVac vaccine has found it 67% effective against symptoms and 80% against death from COVID-19, the South American country’s Health Ministry said Friday.

Ministry adviser Rafael Araos said the study covered 10.5 million people, including 2.5 million who had received both doses of the vaccine and 1.5 million who had received a single dose between Feb. 2 and April 1.

It counted cases starting 14 days after application of the second dose of the vaccine, which in Chile was given 28 days after the first.

The vaccine has been widely used across the world, though not in the United States or Europe.

Araos said it had reduced hospitalizations by 85%, intensive care visits by 89% and deaths by 80%.

It has contracted for 60 million doses of the CoronaVac vaccine produced by Sinovac over three years, and also has been using vaccines produced by Pfizer. About 90% of vaccines used so far in Chile have been CoronaVac.

Authorities reported Thursday that Chile had been a sharp reduction in hospitalization of people 70 or older, something credited to the vaccination campaign among the elderly. But it has also seen “a sustained rise” in hospitalizations of people 59 and younger.

The country has reported 1.1 million confirmed infections of the new virus and nearly 25,000 deaths.



Read More:Big Chile study finds Chinese vaccine slashes COVID deaths

Get real time updates directly on you device, subscribe now.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.